Acrivon Therapeutics, Inc. (ACRV) SEC Filings — 2024
20 SEC filings for Acrivon Therapeutics, Inc. (ACRV) in 2024.
Filings
- Acrivon Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024
- Acrivon Therapeutics Files 8-K Report — 8-K · Oct 11, 2024
- Acrivon Therapeutics Files 8-K — 8-K · Sep 16, 2024
- Acrivon Therapeutics Q2 2024: Cash Down, R&D Up, $100M Raised — 10-Q · Aug 13, 2024
- Acrivon Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Jul 10, 2024
- Acrivon Therapeutics Files 8-K on Security Holder Vote — 8-K · Jun 21, 2024
- Acrivon Therapeutics Files 8-K on Financials — 8-K · May 14, 2024
- Acrivon Therapeutics Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 26, 2024
- Acrivon Therapeutics Files 8-K on Financials and Operations — 8-K · Apr 24, 2024
- Acrivon Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Apr 15, 2024
- RA Capital Amends Acrivon Therapeutics Filing — SC 13D/A · Apr 11, 2024
- Acrivon Therapeutics Announces Material Definitive Agreement — 8-K · Apr 9, 2024
- Acrivon Therapeutics Files 10-K for Fiscal Year Ended December 31, 2023 — 10-K · Mar 28, 2024
- Acrivon Therapeutics Files 8-K on Director Changes and Compensation — 8-K · Mar 4, 2024
- Acrivon Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Acrivon Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Acrivon Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 14, 2024
- Acrivon Therapeutics, Inc. SC 13G/A Filing — SC 13G/A · Feb 13, 2024
- Acrivon Therapeutics Reports Officer/Director Changes, Comp Arrangements — 8-K · Feb 8, 2024
- Acrivon Therapeutics Confirms Emerging Growth Company Status — 8-K · Jan 8, 2024